Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Sanjiv Patel is President and CEO at Relay Therapeutics. OQRO lists 11 transactions filed with the SEC under this name, the latest on Oct 8, 2026, each linked to the official Form 4.
President and CEO
Disclosures on record
11
Companies involved
1
Relay TherapeuticsRLAY
11 disclosures · Dec 2024 – Oct 2026 · 11 sold
Oct 7, 2026Sold~$872Kdisclosed Oct 8
DetailsOfficial recordJul 9, 2025Sold~$153Kdisclosed Jul 10
DetailsOfficial recordJul 9, 2025Sold~$67Kdisclosed Jul 10
DetailsOfficial recordApr 23, 2025Sold~$127Kdisclosed Apr 24
DetailsOfficial recordApr 23, 2025Sold~$55Kdisclosed Apr 24
DetailsOfficial recordFeb 11, 2025Sold~$540Kdisclosed Feb 14
DetailsOfficial recordFeb 13, 2025Sold~$279Kdisclosed Feb 14
DetailsOfficial recordJan 22, 2025Sold~$600Kdisclosed Jan 24
DetailsOfficial recordJan 23, 2025Sold~$598Kdisclosed Jan 24
DetailsOfficial recordJan 21, 2025Sold~$565Kdisclosed Jan 24
DetailsOfficial recordDec 16, 2024Sold~$500Kdisclosed Dec 18
DetailsOfficial recordSanjiv Patel bought shares on the open market in 2020, and has not bought since 2020. Sales in each of the last 5 years.
Sanjiv Patel reported 1 open-market purchase and 32 sales since 2020; purchases in 2020.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $872K1×1 trade |
| 2025 | — | $2.98M9×9 trades |
| 2024 | — | $1.29M3×3 trades |
| 2023 | — | $2.59M6×6 trades |
| 2022 | — | $4.96M13×13 trades |
| 2020 | $500K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
As of the latest filing on , Sanjiv Patel reported holding 670,849 shares of Relay Therapeutics (RLAY), worth about $12.1M at the last close of $18 (Nov 13, 2026): 471,301 held directly and 199,548 through a patel family irrevocable trust of 2019. In the last 12 months, Sanjiv Patel sold $872K in 1 sale.
Relay Therapeutics's proxy statement reports total compensation of $4.65M for Sanjiv Patel for fiscal year 2025, after $13.1M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Apr 28, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Relay Therapeutics RLAY | 670,849 | 471K direct · 200K patel family irrevocable trust of 2019 | $18 | $12.1M | Oct 7, 2026 |
Is this Sanjiv Patel’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Oct 7, 2026, Sanjiv Patel reported holding 670,849 shares of Relay Therapeutics (RLAY), of which 199,548 are held indirectly. At the last close of $18 on Nov 13, 2026, that is about $12.1M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Sanjiv Patel reported 1 open-market sale worth $872K, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Relay Therapeutics's proxy statement reports total compensation of $4.65M for Sanjiv Patel for fiscal year 2025, after $13.1M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
Sanjiv Patel bought shares on the open market in 2020, and has not bought since 2020. Sales in each of the last 5 years.
In SEC filings since 2020: the latest open-market purchase is from 2020; the latest open-market sale is from 2026.
Relay Therapeutics (RLAY), from 2020 to 2026: 1 purchase and 32 sales.
Sanjiv Patel reported 1 open-market purchase and 32 sales here, 2020 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
